Jatenzo Regulatory Status: US, EU, Canada, and UK

United States: Full FDA Approval With a Mandatory REMS

The FDA approved Jatenzo (testosterone undecanoate) capsules on March 27, 2019, under NDA 206089, making it the first oral testosterone product approved in the United States in over 60 years. The approval was restricted to adult males who have low or absent testosterone caused by specific documented medical conditions, not age-related decline alone. This narrow indication reflected FDA concerns about cardiovascular risk in broader testosterone-prescribing patterns.

The key registration trial enrolled 166 hypogonadal men and demonstrated that 87% achieved average serum testosterone concentrations within the eugonadal range (300 to 1,100 ng/dL) after 3 months of twice-daily dosing with food [1]. Dose titration across three levels (158 mg, 198 mg, and 237 mg twice daily, later expanded to 396 mg twice daily) allowed clinicians to individualize therapy based on trough testosterone levels measured at 4 to 6 weeks.

A distinguishing regulatory feature is Jatenzo's mandatory Risk Evaluation and Mitigation Strategy (REMS). The FDA required this program because clinical trial data showed dose-dependent increases in systolic blood pressure, with mean rises of 3 to 5 mmHg at the highest approved dose. Under the REMS, prescribers must be certified, and pharmacies must be specially certified to dispense the drug. Patients require blood pressure monitoring before and during treatment. The REMS also mandates that the prescriber confirm documented hypogonadism from a recognized etiology before initiating therapy, a requirement that goes beyond most other testosterone formulations on the US market.

Jatenzo is classified as a Schedule III controlled substance under the Controlled Substances Act, consistent with all other testosterone products in the US. This classification restricts refill frequency and requires DEA-registered prescribers.

How Jatenzo Works: The SEDDS Formulation

Jatenzo's oral bioavailability problem, the same one that kept oral testosterone off the US market for decades, was solved through a self-emulsifying drug delivery system (SEDDS). Testosterone itself has near-complete first-pass hepatic metabolism when swallowed. Oral testosterone undecanoate partially bypasses hepatic degradation because the long-chain fatty acid ester is absorbed via the intestinal lymphatic system rather than the portal vein.

Older oral TU formulations (Andriol, Restandol) relied on this lymphatic absorption pathway but produced highly variable serum levels depending on the fat content of a meal. Jatenzo's SEDDS technology uses lipid-based excipients that form fine emulsion droplets in the gastrointestinal tract, promoting more consistent lymphatic uptake regardless of meal composition [1]. The result is tighter pharmacokinetic control. In pharmacokinetic studies, Jatenzo produced a mean Cavg of approximately 489 ng/dL at the 237 mg twice-daily dose, with lower intra-patient variability compared to historical data from Andriol Testocaps.

Once absorbed, testosterone undecanoate is cleaved by esterases in the systemic circulation and lymph, releasing free testosterone. That free testosterone then follows normal physiological pathways: binding to androgen receptors in muscle, bone, brain, and reproductive tissues; converting to dihydrotestosterone (DHT) via 5-alpha-reductase; and aromatizing to estradiol via aromatase in adipose tissue. The pharmacological endpoint is identical to injectable or transdermal testosterone. The differentiation is entirely in the delivery route.

European Union: No Jatenzo, but Oral TU Has Been Available Since the 1970s

Jatenzo as a branded product has not been submitted for European Medicines Agency (EMA) authorization. Clarus Therapeutics, the original developer, focused its commercial strategy exclusively on the US market. No Marketing Authorization Application (MAA) was filed with the EMA, and Tolmar (which acquired the Jatenzo brand) has not publicly announced EU regulatory plans.

This does not mean oral testosterone undecanoate is unavailable in Europe. Andriol Testocaps (testosterone undecanoate 40 mg capsules, manufactured by Organon) has held national marketing authorizations across EU member states since the late 1970s. The product is approved for testosterone replacement in male hypogonadism in countries including Germany, France, Italy, Spain, and the Netherlands, among others.

The regulatory distinction matters clinically. Andriol Testocaps uses an oleic acid-based formulation that requires co-administration with a fat-containing meal for adequate absorption. The Endocrine Society's 2018 clinical practice guideline acknowledges oral TU as a therapeutic option but notes the pharmacokinetic variability of older formulations. Andriol's typical dosing is 120 to 160 mg daily in divided doses, substantially different from Jatenzo's 316 to 792 mg total daily dose, reflecting the formulation differences.

EU prescribers can use Andriol Testocaps within the testosterone replacement indication but do not have access to Jatenzo's SEDDS formulation. No REMS-equivalent risk management program exists for Andriol in EU member states, though periodic safety update reports (PSURs) are required under EU pharmacovigilance law, and all testosterone products carry a class-level warning about cardiovascular risk per EMA guidance.

Canada: Andriol Approved Since 1992, No Jatenzo Filing

Health Canada has not received or approved an application for Jatenzo. The Canadian regulatory pathway, a New Drug Submission (NDS), would require Tolmar to submit a full clinical dossier or reference existing US data under a comparative bioavailability approach. As of May 2026, no such filing appears in Health Canada's drug product database or clinical trials registry.

Canadian physicians prescribing oral testosterone undecanoate use Andriol (testosterone undecanoate 40 mg capsules), which has held a Drug Identification Number (DIN) since 1992. The Canadian product monograph specifies a starting dose of 120 to 160 mg daily for 2 to 3 weeks, followed by an individualized maintenance dose of 40 to 120 mg daily.

Canadian regulatory requirements for testosterone products include Schedule IV classification under the Controlled Drugs and Substances Act and mandatory reporting of serious adverse drug reactions through the Canada Vigilance Program. A patient in Canada who specifically wants the Jatenzo SEDDS formulation would need to access it through the Special Access Programme (SAP), which permits importation of non-marketed drugs for individual patients with serious conditions when conventional treatments are unsuitable. The practical barrier is cost: Jatenzo's US wholesale acquisition cost has exceeded $500 per month, and SAP requests for a widely available therapeutic class are rarely granted.

United Kingdom: Restandol Testocaps Under MHRA Oversight

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has not authorized Jatenzo. Following Brexit, the UK regulatory pathway operates independently of the EMA, but no new application for Jatenzo has been filed with the MHRA.

UK clinicians prescribe testosterone undecanoate capsules as Restandol Testocaps (testosterone undecanoate 40 mg capsules), which is the same Organon formulation as EU Andriol Testocaps. The product is indicated for testosterone replacement therapy in male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests. The Summary of Product Characteristics (SmPC) specifies a usual dose of 120 to 160 mg daily for 2 to 3 weeks, then 40 to 120 mg daily maintenance.

UK prescribing operates under NHS frameworks. Testosterone products are available on NHS prescription and are included in the British National Formulary (BNF). NHS England's clinical commissioning guidance for hypogonadism generally favors injectable testosterone undecanoate (Nebido, 1,000 mg every 10 to 14 weeks) or transdermal testosterone gel as first-line options due to cost-effectiveness. Oral Restandol Testocaps, while available, is prescribed less frequently because of its pharmacokinetic variability and the need for twice- or thrice-daily dosing with meals.

The MHRA requires ongoing pharmacovigilance for all testosterone products. A 2014 MHRA Drug Safety Update reinforced guidance that testosterone should only be prescribed to men with documented clinical and biochemical hypogonadism, not for age-related testosterone decline. This position aligns with the FDA's 2015 label changes requiring all testosterone products to carry a warning about possible cardiovascular risk.

Why Jatenzo Stayed US-Only: Commercial and Regulatory Factors

Several factors explain why Jatenzo's developer chose not to pursue approvals outside the US. Clarus Therapeutics, a small pharmaceutical company, went public in December 2021 and filed for bankruptcy in September 2023. The limited commercial runway made multi-country regulatory filings financially impractical. Each new jurisdiction would have required separate clinical pharmacokinetic bridging studies, local manufacturing site inspections, and potentially additional safety data to meet region-specific requirements.

The competitive environment also plays a role. In the EU, Canada, and UK, oral testosterone undecanoate has been a generic commodity for years. Andriol/Restandol Testocaps, while pharmacokinetically inferior to Jatenzo's SEDDS formulation, is priced far below what Jatenzo commands in the US. Tolmar would face the challenge of demonstrating sufficient clinical superiority to justify a premium price in markets with established, low-cost oral TU options and strong payor resistance to higher-priced alternatives.

A regulatory note: injectable testosterone undecanoate (Aveed in the US, Nebido in Europe and the UK) is a separate product with its own approval history. Aveed received FDA approval in 2014 and carries its own REMS due to risk of pulmonary oil microembolism and anaphylaxis. It should not be confused with oral testosterone undecanoate products.

Comparing Regulatory Frameworks: Key Differences That Affect Patient Access

The divergence in oral TU availability across markets reflects different regulatory philosophies toward testosterone therapy. The FDA's REMS requirement for Jatenzo is the strictest framework applied to any oral testosterone product globally. No other country imposes a comparable mandatory risk management program on oral TU capsules.

In the EU, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the cardiovascular safety of testosterone-containing medicines in 2014 and concluded that the benefits continued to outweigh the risks when used according to approved indications, with updated product information. No additional risk management measures beyond standard pharmacovigilance were mandated.

Health Canada and the MHRA have adopted positions similar to the EMA: standard pharmacovigilance with updated cardiovascular warnings, but no prescriber certification or pharmacy certification requirements.

For US patients and clinicians, the practical effect of the REMS is an additional administrative barrier. The REMS certification process requires prescribers to complete training and attest to understanding the cardiovascular risks. Pharmacies must enroll in the program and verify prescriber certification before dispensing. These steps add processing time and limit the number of retail pharmacies that carry Jatenzo.

The 2022 cardiovascular outcomes trial (TRAVERSE, N=5,204) demonstrated that testosterone replacement therapy (using transdermal gel) did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease. While TRAVERSE did not study Jatenzo specifically, its findings may eventually influence FDA reconsideration of the REMS requirements for testosterone products broadly. The Endocrine Society incorporated TRAVERSE data into its updated guidance, noting that the trial provided reassurance regarding cardiovascular safety of testosterone replacement within approved indications [2].

Dose Form Comparison Across Jurisdictions

Clinicians selecting oral testosterone undecanoate should understand the formulation differences. Jatenzo capsules contain 158 mg, 198 mg, or 237 mg of testosterone undecanoate per capsule (equivalent to approximately 100 mg, 125 mg, or 150 mg of testosterone undecanoate, with the balance being SEDDS excipients). The recommended starting dose is 237 mg twice daily with food, titrated based on serum testosterone measured after 4 to 6 weeks.

Andriol Testocaps and Restandol Testocaps contain 40 mg testosterone undecanoate per capsule in an oleic acid/propylene glycol laurate vehicle. The typical starting dose is 120 to 160 mg daily (3 to 4 capsules) divided into two doses, taken with meals. The lower total daily TU dose reflects poorer bioavailability: much of the orally administered testosterone undecanoate in the older formulation is lost to incomplete lymphatic absorption and partial first-pass metabolism of the portion absorbed via the portal vein.

A head-to-head pharmacokinetic comparison has not been conducted in a single randomized trial. Indirect comparison of published data suggests that Jatenzo achieves more consistent serum testosterone within the eugonadal range. The Swerdloff 2020 trial reported an 87% eugonadal achievement rate for Jatenzo [1], while historical data for Andriol Testocaps shows eugonadal rates of approximately 65% to 75%, with substantial meal-dependent variability.

The latest prescribing information from the FDA label for Jatenzo details the dose titration algorithm, blood pressure monitoring schedule, and REMS-mandated elements. Prescribers unfamiliar with the REMS should review the FDA REMS page before writing the first prescription.